H.C. Wainwright raises Evaxion Biotech stock price target to $16 on Merck deal
PositiveFinancial Markets

H.C. Wainwright has raised the stock price target for Evaxion Biotech to $16 following a significant deal with Merck. This adjustment reflects confidence in Evaxion's potential growth and the positive impact of the partnership on its future prospects. Investors are likely to view this as a promising sign for the company's trajectory in the biotech sector.
— Curated by the World Pulse Now AI Editorial System